Everolimus in the treatment of metastatic thymic epithelial tumors
Optimal treatment in the relapsed-refractory setting for patients with advanced thymic epithelial tumors (TETs) is poorly understood. The current standard of care first line treatment for advanced thymoma and thymic carcinoma is a platinum-based regimen based on data from several small single-arm phase 2 studies. Cyclophosphamide/doxorubicin/cisplatin (CAP) and carboplatin/paclitaxel are both options for TETs, although the former is more commonly used for advanced thymoma [1,2] and the latter for thymic carcinoma [3].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Jessica A. Hellyer, Madhu M. Ouseph, Sukhmani K. Padda, Heather A. Wakelee Source Type: research